Long COVID and COVID-19-associated cystitis (CAC)
Purpose There is scarce literature regarding genitourinary symptoms in COVID-19, especially post-acute disease otherwise known as Long COVID. We identified recovered COVID-19 patients presenting with new or worsening overactive bladder symptoms, known as COVID-19-associated cystitis (CAC). Methods W...
Gespeichert in:
Veröffentlicht in: | International urology and nephrology 2022-01, Vol.54 (1), p.17-21 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 21 |
---|---|
container_issue | 1 |
container_start_page | 17 |
container_title | International urology and nephrology |
container_volume | 54 |
creator | Lamb, Laura E. Timar, Ryan Wills, Melissa Dhar, Sorabh Lucas, Steve M. Komnenov, Dragana Chancellor, Michael B. Dhar, Nivedita |
description | Purpose
There is scarce literature regarding genitourinary symptoms in COVID-19, especially post-acute disease otherwise known as Long COVID. We identified recovered COVID-19 patients presenting with new or worsening overactive bladder symptoms, known as COVID-19-associated cystitis (CAC).
Methods
We used the American Urological Association Urology Care Foundation Overactive Bladder (OAB) Assessment Tool to screen COVID-19 recovered patients presenting with urological complaints at our urban-located institution from 5/22/2020 to 12/31/2020. Patients 10–14 weeks post-discharge responded to 5 symptom and 4 quality-of-life (QoL) questions. We reported median symptom scores, as well as QoL scores, based on new or worsening urinary symptoms, and by sex.
Results
We identified 350 patients with de novo or worsening OAB symptoms 10–14 weeks after hospitalization with COVID-19. The median total OAB symptom score in both men and women was 18. The median total QoL score for both men and women was 19. Patients with worsening OAB symptoms had a median pre-COVID-19 symptom score of 8 (4–10) compared to post-COVID-19 median symptom score of 19 (17–21). Median age was 64.5 (range 47–82). Median hospital length-of-stay was 10 days (range 5–30).
Conclusion
We report survey-based results of patients suffering from new or worsening OAB symptoms months after their hospitalization from COVID-19. Future studies with larger sample sizes and more extensive testing will hopefully elucidate the specific pathophysiology of OAB symptoms in the context of long COVID so urologists can timely and appropriately treat their patients. |
doi_str_mv | 10.1007/s11255-021-03030-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8597545</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2616788028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-554d7eb670d4a5ebaea644f47ec2ed2eec35eec8607144a94504ff8f4151598b3</originalsourceid><addsrcrecordid>eNp9kV1LwzAUhoMobk7_gBdS8GZeRPPZpDfCqF-DwW7U25C26ezompm0wv690c75cSGBk3DOc96TwwvAKUaXGCFx5TEmnENEMEQ0HEj2wBBzQSHhku2DYchhiGNCB-DI-yVCKJEIHYIBZUIKIckQ4JltFlE6f57eRLop-hfECdTe27zSrSmifOPbqq18NE4n6cUxOCh17c3J9h6Bp7vbx_QBzub303QygzkTrIWcs0KYLBaoYJqbTBsdM1YyYXJiCmJMTnkIMkYCM6YTxhErS1kyzDFPZEZH4LrXXXfZyhS5aVqna7V21Uq7jbK6Ur8rTfWiFvZNSZ4IzngQGG8FnH3tjG_VqvK5qWvdGNt5RcIYTmMpaEDP_6BL27kmrKdIjGMhJSIyUKSncme9d6bcfQYj9eGI6h1RwRH16Ygioens5xq7li8LAkB7wIdSszDue_Y_su8N6pOC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616788028</pqid></control><display><type>article</type><title>Long COVID and COVID-19-associated cystitis (CAC)</title><source>MEDLINE</source><source>Springer Journals</source><creator>Lamb, Laura E. ; Timar, Ryan ; Wills, Melissa ; Dhar, Sorabh ; Lucas, Steve M. ; Komnenov, Dragana ; Chancellor, Michael B. ; Dhar, Nivedita</creator><creatorcontrib>Lamb, Laura E. ; Timar, Ryan ; Wills, Melissa ; Dhar, Sorabh ; Lucas, Steve M. ; Komnenov, Dragana ; Chancellor, Michael B. ; Dhar, Nivedita</creatorcontrib><description>Purpose
There is scarce literature regarding genitourinary symptoms in COVID-19, especially post-acute disease otherwise known as Long COVID. We identified recovered COVID-19 patients presenting with new or worsening overactive bladder symptoms, known as COVID-19-associated cystitis (CAC).
Methods
We used the American Urological Association Urology Care Foundation Overactive Bladder (OAB) Assessment Tool to screen COVID-19 recovered patients presenting with urological complaints at our urban-located institution from 5/22/2020 to 12/31/2020. Patients 10–14 weeks post-discharge responded to 5 symptom and 4 quality-of-life (QoL) questions. We reported median symptom scores, as well as QoL scores, based on new or worsening urinary symptoms, and by sex.
Results
We identified 350 patients with de novo or worsening OAB symptoms 10–14 weeks after hospitalization with COVID-19. The median total OAB symptom score in both men and women was 18. The median total QoL score for both men and women was 19. Patients with worsening OAB symptoms had a median pre-COVID-19 symptom score of 8 (4–10) compared to post-COVID-19 median symptom score of 19 (17–21). Median age was 64.5 (range 47–82). Median hospital length-of-stay was 10 days (range 5–30).
Conclusion
We report survey-based results of patients suffering from new or worsening OAB symptoms months after their hospitalization from COVID-19. Future studies with larger sample sizes and more extensive testing will hopefully elucidate the specific pathophysiology of OAB symptoms in the context of long COVID so urologists can timely and appropriately treat their patients.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-021-03030-2</identifier><identifier>PMID: 34787782</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Aged ; Aged, 80 and over ; Coronaviruses ; COVID-19 ; COVID-19 - complications ; COVID-19 - epidemiology ; COVID-19 - etiology ; Cystitis ; Cystitis - epidemiology ; Cystitis - etiology ; Female ; Humans ; Incidence ; Long COVID ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrology ; Pandemics ; Patients ; Quality of Life ; SARS-CoV-2 ; United States - epidemiology ; Urology ; Urology - Original Paper</subject><ispartof>International urology and nephrology, 2022-01, Vol.54 (1), p.17-21</ispartof><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021</rights><rights>2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.</rights><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-554d7eb670d4a5ebaea644f47ec2ed2eec35eec8607144a94504ff8f4151598b3</citedby><cites>FETCH-LOGICAL-c474t-554d7eb670d4a5ebaea644f47ec2ed2eec35eec8607144a94504ff8f4151598b3</cites><orcidid>0000-0001-8855-4291 ; 0000-0001-9480-8972 ; 0000-0003-0386-4165 ; 0000-0002-1497-7643</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-021-03030-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-021-03030-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34787782$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamb, Laura E.</creatorcontrib><creatorcontrib>Timar, Ryan</creatorcontrib><creatorcontrib>Wills, Melissa</creatorcontrib><creatorcontrib>Dhar, Sorabh</creatorcontrib><creatorcontrib>Lucas, Steve M.</creatorcontrib><creatorcontrib>Komnenov, Dragana</creatorcontrib><creatorcontrib>Chancellor, Michael B.</creatorcontrib><creatorcontrib>Dhar, Nivedita</creatorcontrib><title>Long COVID and COVID-19-associated cystitis (CAC)</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Purpose
There is scarce literature regarding genitourinary symptoms in COVID-19, especially post-acute disease otherwise known as Long COVID. We identified recovered COVID-19 patients presenting with new or worsening overactive bladder symptoms, known as COVID-19-associated cystitis (CAC).
Methods
We used the American Urological Association Urology Care Foundation Overactive Bladder (OAB) Assessment Tool to screen COVID-19 recovered patients presenting with urological complaints at our urban-located institution from 5/22/2020 to 12/31/2020. Patients 10–14 weeks post-discharge responded to 5 symptom and 4 quality-of-life (QoL) questions. We reported median symptom scores, as well as QoL scores, based on new or worsening urinary symptoms, and by sex.
Results
We identified 350 patients with de novo or worsening OAB symptoms 10–14 weeks after hospitalization with COVID-19. The median total OAB symptom score in both men and women was 18. The median total QoL score for both men and women was 19. Patients with worsening OAB symptoms had a median pre-COVID-19 symptom score of 8 (4–10) compared to post-COVID-19 median symptom score of 19 (17–21). Median age was 64.5 (range 47–82). Median hospital length-of-stay was 10 days (range 5–30).
Conclusion
We report survey-based results of patients suffering from new or worsening OAB symptoms months after their hospitalization from COVID-19. Future studies with larger sample sizes and more extensive testing will hopefully elucidate the specific pathophysiology of OAB symptoms in the context of long COVID so urologists can timely and appropriately treat their patients.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - etiology</subject><subject>Cystitis</subject><subject>Cystitis - epidemiology</subject><subject>Cystitis - etiology</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Long COVID</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Quality of Life</subject><subject>SARS-CoV-2</subject><subject>United States - epidemiology</subject><subject>Urology</subject><subject>Urology - Original Paper</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kV1LwzAUhoMobk7_gBdS8GZeRPPZpDfCqF-DwW7U25C26ezompm0wv690c75cSGBk3DOc96TwwvAKUaXGCFx5TEmnENEMEQ0HEj2wBBzQSHhku2DYchhiGNCB-DI-yVCKJEIHYIBZUIKIckQ4JltFlE6f57eRLop-hfECdTe27zSrSmifOPbqq18NE4n6cUxOCh17c3J9h6Bp7vbx_QBzub303QygzkTrIWcs0KYLBaoYJqbTBsdM1YyYXJiCmJMTnkIMkYCM6YTxhErS1kyzDFPZEZH4LrXXXfZyhS5aVqna7V21Uq7jbK6Ur8rTfWiFvZNSZ4IzngQGG8FnH3tjG_VqvK5qWvdGNt5RcIYTmMpaEDP_6BL27kmrKdIjGMhJSIyUKSncme9d6bcfQYj9eGI6h1RwRH16Ygioens5xq7li8LAkB7wIdSszDue_Y_su8N6pOC</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Lamb, Laura E.</creator><creator>Timar, Ryan</creator><creator>Wills, Melissa</creator><creator>Dhar, Sorabh</creator><creator>Lucas, Steve M.</creator><creator>Komnenov, Dragana</creator><creator>Chancellor, Michael B.</creator><creator>Dhar, Nivedita</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8855-4291</orcidid><orcidid>https://orcid.org/0000-0001-9480-8972</orcidid><orcidid>https://orcid.org/0000-0003-0386-4165</orcidid><orcidid>https://orcid.org/0000-0002-1497-7643</orcidid></search><sort><creationdate>20220101</creationdate><title>Long COVID and COVID-19-associated cystitis (CAC)</title><author>Lamb, Laura E. ; Timar, Ryan ; Wills, Melissa ; Dhar, Sorabh ; Lucas, Steve M. ; Komnenov, Dragana ; Chancellor, Michael B. ; Dhar, Nivedita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-554d7eb670d4a5ebaea644f47ec2ed2eec35eec8607144a94504ff8f4151598b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - etiology</topic><topic>Cystitis</topic><topic>Cystitis - epidemiology</topic><topic>Cystitis - etiology</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Long COVID</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Quality of Life</topic><topic>SARS-CoV-2</topic><topic>United States - epidemiology</topic><topic>Urology</topic><topic>Urology - Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamb, Laura E.</creatorcontrib><creatorcontrib>Timar, Ryan</creatorcontrib><creatorcontrib>Wills, Melissa</creatorcontrib><creatorcontrib>Dhar, Sorabh</creatorcontrib><creatorcontrib>Lucas, Steve M.</creatorcontrib><creatorcontrib>Komnenov, Dragana</creatorcontrib><creatorcontrib>Chancellor, Michael B.</creatorcontrib><creatorcontrib>Dhar, Nivedita</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamb, Laura E.</au><au>Timar, Ryan</au><au>Wills, Melissa</au><au>Dhar, Sorabh</au><au>Lucas, Steve M.</au><au>Komnenov, Dragana</au><au>Chancellor, Michael B.</au><au>Dhar, Nivedita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long COVID and COVID-19-associated cystitis (CAC)</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>54</volume><issue>1</issue><spage>17</spage><epage>21</epage><pages>17-21</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>Purpose
There is scarce literature regarding genitourinary symptoms in COVID-19, especially post-acute disease otherwise known as Long COVID. We identified recovered COVID-19 patients presenting with new or worsening overactive bladder symptoms, known as COVID-19-associated cystitis (CAC).
Methods
We used the American Urological Association Urology Care Foundation Overactive Bladder (OAB) Assessment Tool to screen COVID-19 recovered patients presenting with urological complaints at our urban-located institution from 5/22/2020 to 12/31/2020. Patients 10–14 weeks post-discharge responded to 5 symptom and 4 quality-of-life (QoL) questions. We reported median symptom scores, as well as QoL scores, based on new or worsening urinary symptoms, and by sex.
Results
We identified 350 patients with de novo or worsening OAB symptoms 10–14 weeks after hospitalization with COVID-19. The median total OAB symptom score in both men and women was 18. The median total QoL score for both men and women was 19. Patients with worsening OAB symptoms had a median pre-COVID-19 symptom score of 8 (4–10) compared to post-COVID-19 median symptom score of 19 (17–21). Median age was 64.5 (range 47–82). Median hospital length-of-stay was 10 days (range 5–30).
Conclusion
We report survey-based results of patients suffering from new or worsening OAB symptoms months after their hospitalization from COVID-19. Future studies with larger sample sizes and more extensive testing will hopefully elucidate the specific pathophysiology of OAB symptoms in the context of long COVID so urologists can timely and appropriately treat their patients.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>34787782</pmid><doi>10.1007/s11255-021-03030-2</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-8855-4291</orcidid><orcidid>https://orcid.org/0000-0001-9480-8972</orcidid><orcidid>https://orcid.org/0000-0003-0386-4165</orcidid><orcidid>https://orcid.org/0000-0002-1497-7643</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0301-1623 |
ispartof | International urology and nephrology, 2022-01, Vol.54 (1), p.17-21 |
issn | 0301-1623 1573-2584 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8597545 |
source | MEDLINE; Springer Journals |
subjects | Aged Aged, 80 and over Coronaviruses COVID-19 COVID-19 - complications COVID-19 - epidemiology COVID-19 - etiology Cystitis Cystitis - epidemiology Cystitis - etiology Female Humans Incidence Long COVID Male Medicine Medicine & Public Health Middle Aged Nephrology Pandemics Patients Quality of Life SARS-CoV-2 United States - epidemiology Urology Urology - Original Paper |
title | Long COVID and COVID-19-associated cystitis (CAC) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T06%3A53%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20COVID%20and%20COVID-19-associated%20cystitis%20(CAC)&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Lamb,%20Laura%20E.&rft.date=2022-01-01&rft.volume=54&rft.issue=1&rft.spage=17&rft.epage=21&rft.pages=17-21&rft.issn=0301-1623&rft.eissn=1573-2584&rft_id=info:doi/10.1007/s11255-021-03030-2&rft_dat=%3Cproquest_pubme%3E2616788028%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616788028&rft_id=info:pmid/34787782&rfr_iscdi=true |